Liang Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Liang Wu has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Asmaa Ali
Department of Laboratory Medicine, School of Medicine, Jiangsu University, Zhenjiang, China
4 shared publications - Mai Mahmoud Saleh
Department of Chest Disease, Faculty of Medicine, Tanta University, Tanta, Egypt
3 shared publications - Seham Ezzat Fathy Elfeky
Department of Chest Disease, Faculty of Medicine, Tanta University, Tanta, Egypt
2 shared publications - Abdulaziz Alghulayqah
Department of Medicine, College of Medicine, Qassim University, Buraidah, Saudi Arabia
1 shared publication Abeer M. Eissa
Department of Allergy, Al-Rashid Allergy Center, KMOH, Kuwait City, Kuwait
1 shared publication- Abeer Mohamed Eissa
Department of Pulmonary Medicine, Abbassia Chest Hospital, EMOH, Cairo, Egypt
1 shared publication
Latest Publications
- Open Access
- 18 September 2026
- Published by Springer Nature in The Egyptian Journal of Bronchology
- Vol. 20 (1) , 166
Diagnostic accuracy of shear wave elastography and ultrasound-derived indices in interstitial lung disease: novel insights into connective tissue disease-associated interstitial lung disease and idiopathic pulmonary fibrosis
Background: This study aimed to evaluate the diagnostic accuracy of shear wave elastography (SWE) and ultrasound-derived indices in detecting and distinguishing interstitial lung disease (ILD) subtypes. Methods: Sixty patients with connective tissue disease-associated interstitial lung disease (CTD-ILD) and idiopathic pulmonary fibrosis (IPF), and 30 healthy controls underwent comprehensive pulmonary function testing, six-minute walk tests (6MWT), arterial blood gas analysis, and thoracic imaging. Radiological parameters assessed included diaphragmatic thickness and excursion, SWE stiffness values, and computed tomography (CT) scoring. Receiver operating characteristic (ROC) curve analysis was performed to determine the diagnostic performance of each parameter. Results: All groups were predominantly female, with no significant sex distribution differences ( p = 0.66). The CTD-ILD group was significantly younger than both the IPF and control groups ( p = 0.003). Both ILD groups demonstrated significantly reduced VC% and FVC% compared to controls ( p < 0.001), with preserved FEV 1 /FVC ratios. Functional capacity was impaired in ILD patients, who showed higher alveolar–arterial gradients, lower oxygen saturations, and shorter 6MWT distances ( p < 0.001). SWE and ultrasound-derived indices revealed high diagnostic performance in detecting diffuse parenchymal lung disease (DP-ILD). The highest accuracy was achieved by TVDE and SWEC (AUC = 1.00), followed by SWEE (AUC = 0.97), DTF (AUC = 0.96), and CT score (AUC = 0.92). Cutoff-based analysis showed DTF < 73.50 yielded 93% sensitivity and 100% specificity, while SWEC > 1.95 and SWEE > 15.75 demonstrated ≥ 97% accuracy across all metrics. Comparison between IPF and CTD-ILD revealed better pulmonary function and longer 6MWT distances in RA-ILD ( p < 0.05), while diaphragmatic excursion was greater in IPF ( p < 0.05). However, gas exchange and SWE indices showed no significant intergroup differences. MDE and TVDE offered modest discriminatory value (AUCs 0.71 and 0.69, respectively), with cutoff optimization necessary for balancing sensitivity and specificity. Correlations revealed that higher SWEC and SWEE values were strongly linked to worse pulmonary function, gas exchange, exercise tolerance, diaphragmatic dysfunction, and more extensive fibrosis. Conclusion: In this single-center study, SWE and ultrasound-derived indices demonstrated excellent diagnostic performance for detecting ILD and showed strong correlations with clinical, functional, and radiological measures, supporting their potential as non-invasive adjunctive tools. However, their ability to differentiate CTD-ILD from IPF remained limited. Given the relatively small sample size and single-center design, these findings should be considered preliminary and require validation in larger, multicenter prospective studies before routine clinical implementation.
- 18 September 2026
- Published by Springer Nature in The Egyptian Journal of Bronchology
- Vol. 20 (1) , 166
Open AccessDiagnostic accuracy of shear wave elastography and ultrasound-derived indices in interstitial lung disease: novel insights into connective tissue disease-associated interstitial lung disease and idiopathic pulmonary fibrosis
Background: This study aimed to evaluate the diagnostic accuracy of shear wave elastography (SWE) and ultrasound-derived indices in detecting and distinguishing interstitial lung disease (ILD) subtypes. Methods: Sixty patients with connective tissue disease-associated interstitial lung disease (CTD-ILD) and idiopathic pulmonary fibrosis (IPF), and 30 healthy controls underwent comprehensive pulmonary function testing, six-minute walk tests (6MWT), arterial blood gas analysis, and thoracic imaging. Radiological parameters assessed included diaphragmatic thickness and excursion, SWE stiffness values, and computed tomography (CT) scoring. Receiver operating characteristic (ROC) curve analysis was performed to determine the diagnostic performance of each parameter. Results: All groups were predominantly female, with no significant sex distribution differences ( p = 0.66). The CTD-ILD group was significantly younger than both the IPF and control groups ( p = 0.003). Both ILD groups demonstrated significantly reduced VC% and FVC% compared to controls ( p < 0.001), with preserved FEV 1 /FVC ratios. Functional capacity was impaired in ILD patients, who showed higher alveolar–arterial gradients, lower oxygen saturations, and shorter 6MWT distances ( p < 0.001). SWE and ultrasound-derived indices revealed high diagnostic performance in detecting diffuse parenchymal lung disease (DP-ILD). The highest accuracy was achieved by TVDE and SWEC (AUC = 1.00), followed by SWEE (AUC = 0.97), DTF (AUC = 0.96), and CT score (AUC = 0.92). Cutoff-based analysis showed DTF < 73.50 yielded 93% sensitivity and 100% specificity, while SWEC > 1.95 and SWEE > 15.75 demonstrated ≥ 97% accuracy across all metrics. Comparison between IPF and CTD-ILD revealed better pulmonary function and longer 6MWT distances in RA-ILD ( p < 0.05), while diaphragmatic excursion was greater in IPF ( p < 0.05). However, gas exchange and SWE indices showed no significant intergroup differences. MDE and TVDE offered modest discriminatory value (AUCs 0.71 and 0.69, respectively), with cutoff optimization necessary for balancing sensitivity and specificity. Correlations revealed that higher SWEC and SWEE values were strongly linked to worse pulmonary function, gas exchange, exercise tolerance, diaphragmatic dysfunction, and more extensive fibrosis. Conclusion: In this single-center study, SWE and ultrasound-derived indices demonstrated excellent diagnostic performance for detecting ILD and showed strong correlations with clinical, functional, and radiological measures, supporting their potential as non-invasive adjunctive tools. However, their ability to differentiate CTD-ILD from IPF remained limited. Given the relatively small sample size and single-center design, these findings should be considered preliminary and require validation in larger, multicenter prospective studies before routine clinical implementation.
- Open Access
- 11 September 2025
- Published by Springer Nature in The Egyptian Journal of Bronchology
- Vol. 19 (1) , 1-12
Echocardiographic prevalence of pulmonary arterial hypertension in end-stage liver disease and its correlation with post-transplant mortality: when does the pulmonary artery catheter matter?
Background and objectives: Liver transplantation (LT) is the gold standard treatment for end-stage liver disease (ESLD), but pulmonary arterial hypertension (PAH) can significantly affect post-transplant outcomes. While echocardiography provides a non-invasive screening tool for PAH, the role of invasive pulmonary artery catheterization (PAC) in these patients remains unclear. This study aimed to assess the prevalence of PAH in ESLD patients using echocardiography and explore its correlation with post-transplant mortality. Methods: This retrospective cohort study, conducted at the Specialized Center for LT, included ESLD patients preparing for LT from January 2021 to December 2023. Data were collected from patient records, including echocardiographic assessments of right ventricular function, pulmonary function tests, chest imaging, and laboratory evaluations. In-hospital and 1-year mortality rates were also recorded. Results: Seventy-five ESLD patients undergoing LT had a mean age of 51.18 ± 11.83 years, with 68% male predominance. Chronic viral hepatitis, cryptogenic cirrhosis, and non-alcoholic steatohepatitis were the primary causes of liver failure, and hepatocellular carcinoma was present in 18.67%. Comorbidities were infrequent, with diabetes in 24%. Echocardiographic assessment revealed moderate to severe PAH in 53.33% of patients, with 17.33% exhibiting explicit PAH based on pulmonary artery acceleration time (PAAT) and right ventricular systolic pressure (RVSP). A significant negative correlation was found between PAAT and RVSP (r = − 0.52, p < 0.001). Mortality rate was 24%, with half occurring within 30 days and the other half within a year. PAH correlated with increased overall and short-term mortality. Predictors of mortality included elevated creatinine, chronic kidney disease, reduced AST levels, and prolonged prothrombin time. Shorter PAAT was a significant predictor of mortality, with a PAAT < 94 ms showing high specificity but low sensitivity, while a PAAT < 103.5 ms had high sensitivity but lower specificity. Conclusion: A significant prevalence of PAH was observed in patients with ESLD, with a notable correlation between PAH and both overall and short-term mortality following LT. Given the high mortality risk associated with PAH, especially in patients with a PAAT < 94 ms, the study advocates for further hemodynamic assessment using pulmonary artery catheterization in this group before transplantation. This approach may enhance risk stratification, enabling more targeted interventions that could ultimately improve post-transplant outcomes and survival rates.
- 11 September 2025
- Published by Springer Nature in The Egyptian Journal of Bronchology
- Vol. 19 (1) , 1-12
Open AccessEchocardiographic prevalence of pulmonary arterial hypertension in end-stage liver disease and its correlation with post-transplant mortality: when does the pulmonary artery catheter matter?
Background and objectives: Liver transplantation (LT) is the gold standard treatment for end-stage liver disease (ESLD), but pulmonary arterial hypertension (PAH) can significantly affect post-transplant outcomes. While echocardiography provides a non-invasive screening tool for PAH, the role of invasive pulmonary artery catheterization (PAC) in these patients remains unclear. This study aimed to assess the prevalence of PAH in ESLD patients using echocardiography and explore its correlation with post-transplant mortality. Methods: This retrospective cohort study, conducted at the Specialized Center for LT, included ESLD patients preparing for LT from January 2021 to December 2023. Data were collected from patient records, including echocardiographic assessments of right ventricular function, pulmonary function tests, chest imaging, and laboratory evaluations. In-hospital and 1-year mortality rates were also recorded. Results: Seventy-five ESLD patients undergoing LT had a mean age of 51.18 ± 11.83 years, with 68% male predominance. Chronic viral hepatitis, cryptogenic cirrhosis, and non-alcoholic steatohepatitis were the primary causes of liver failure, and hepatocellular carcinoma was present in 18.67%. Comorbidities were infrequent, with diabetes in 24%. Echocardiographic assessment revealed moderate to severe PAH in 53.33% of patients, with 17.33% exhibiting explicit PAH based on pulmonary artery acceleration time (PAAT) and right ventricular systolic pressure (RVSP). A significant negative correlation was found between PAAT and RVSP (r = − 0.52, p < 0.001). Mortality rate was 24%, with half occurring within 30 days and the other half within a year. PAH correlated with increased overall and short-term mortality. Predictors of mortality included elevated creatinine, chronic kidney disease, reduced AST levels, and prolonged prothrombin time. Shorter PAAT was a significant predictor of mortality, with a PAAT < 94 ms showing high specificity but low sensitivity, while a PAAT < 103.5 ms had high sensitivity but lower specificity. Conclusion: A significant prevalence of PAH was observed in patients with ESLD, with a notable correlation between PAH and both overall and short-term mortality following LT. Given the high mortality risk associated with PAH, especially in patients with a PAAT < 94 ms, the study advocates for further hemodynamic assessment using pulmonary artery catheterization in this group before transplantation. This approach may enhance risk stratification, enabling more targeted interventions that could ultimately improve post-transplant outcomes and survival rates.
- Open Access
- 10 February 2025
- Published by Springer Nature in The Egyptian Journal of Bronchology
- Vol. 19 (1) , 1-11
Glycated Hemoglobin: a promising biomarker for predicting acute exacerbation and short-term mortality of chronic obstructive pulmonary disease
Background and objectives: Chronic obstructive pulmonary disease (COPD) is a prevalent respiratory condition, often complicated by frequent exacerbations and increased mortality risk. COPD patients also had a higher risk for developing diabetes mellites. Recently, the studies showed promising utility of HbA1C in identifying patients at heightened risk of critical illnesses. This study evaluated the diagnostic and prognostic value of glycated hemoglobin (HbA1c) in predicting COPD exacerbation and short-term mortality. Methods: A prospective cohort study involved 184 COPD patients. Patients were categorized as either stable or experiencing an acute exacerbation. Demographic and laboratory data, including HbA1c levels, were collected. Results: HbA1c levels were significantly elevated in COPD patients experiencing exacerbations. Factors influencing HbA1c levels included lower oxygen saturation upon admission, use of home oxygen, lymphocyte count, CRP levels, diabetes, and ischemic heart disease (IHD). HbA1c emerged as a strong predictor of both COPD exacerbation and short-term mortality. In the unadjusted model, HbA1c was associated with an increased risk of exacerbation (OR = 1.59, p = 0.001) and remained significant after adjusting for other variables (OR = 2.25, p = 0.03). Similarly, HbA1c was a significant predictor of mortality in both the unadjusted (OR = 1.44, p = 0.001) and adjusted models (OR = 1.66, p = 0.001). Notably, the use of home oxygen was associated with a lower risk of both exacerbation and mortality. Other risk factors for exacerbation included lower oxygen saturation, male sex, IHD, and a history of previous exacerbations. The mortality rate was significantly higher in patients who had experienced recent exacerbations. Conclusion: Elevated HbA1c levels were consistently associated with a higher risk of adverse outcomes, even after adjusting for other significant factors. This highlights the importance of routine HbA1c monitoring in COPD management, particularly in patients with a history of exacerbations or comorbid conditions like diabetes and ischemic heart disease. Additionally, the protective effect of home oxygen therapy against exacerbations and mortality suggests it should be considered as a key component in the management strategy for high-risk COPD patients.
- 10 February 2025
- Published by Springer Nature in The Egyptian Journal of Bronchology
- Vol. 19 (1) , 1-11
Open AccessGlycated Hemoglobin: a promising biomarker for predicting acute exacerbation and short-term mortality of chronic obstructive pulmonary disease
Background and objectives: Chronic obstructive pulmonary disease (COPD) is a prevalent respiratory condition, often complicated by frequent exacerbations and increased mortality risk. COPD patients also had a higher risk for developing diabetes mellites. Recently, the studies showed promising utility of HbA1C in identifying patients at heightened risk of critical illnesses. This study evaluated the diagnostic and prognostic value of glycated hemoglobin (HbA1c) in predicting COPD exacerbation and short-term mortality. Methods: A prospective cohort study involved 184 COPD patients. Patients were categorized as either stable or experiencing an acute exacerbation. Demographic and laboratory data, including HbA1c levels, were collected. Results: HbA1c levels were significantly elevated in COPD patients experiencing exacerbations. Factors influencing HbA1c levels included lower oxygen saturation upon admission, use of home oxygen, lymphocyte count, CRP levels, diabetes, and ischemic heart disease (IHD). HbA1c emerged as a strong predictor of both COPD exacerbation and short-term mortality. In the unadjusted model, HbA1c was associated with an increased risk of exacerbation (OR = 1.59, p = 0.001) and remained significant after adjusting for other variables (OR = 2.25, p = 0.03). Similarly, HbA1c was a significant predictor of mortality in both the unadjusted (OR = 1.44, p = 0.001) and adjusted models (OR = 1.66, p = 0.001). Notably, the use of home oxygen was associated with a lower risk of both exacerbation and mortality. Other risk factors for exacerbation included lower oxygen saturation, male sex, IHD, and a history of previous exacerbations. The mortality rate was significantly higher in patients who had experienced recent exacerbations. Conclusion: Elevated HbA1c levels were consistently associated with a higher risk of adverse outcomes, even after adjusting for other significant factors. This highlights the importance of routine HbA1c monitoring in COPD management, particularly in patients with a history of exacerbations or comorbid conditions like diabetes and ischemic heart disease. Additionally, the protective effect of home oxygen therapy against exacerbations and mortality suggests it should be considered as a key component in the management strategy for high-risk COPD patients.
- Open Access
- 13 June 2024
- Published by Springer Nature in The Egyptian Journal of Bronchology
- Vol. 18 (1) , 1-13
Hematological profiles and mortality risk in critically ill and drug-resistant tuberculosis patients: insights from a longitudinal study
Background: While tuberculosis (TB) remains a significant global health threat, data on mortality in critically ill TB patients and those with drug-resistant TB (DR-TB) is limited. This study explores hematological profiles of critically ill TB patients and those with DR-TB, investigating associations with in-hospital and short-term mortality. Methods: A longitudinal study of 269 patients with confirmed TB evaluated baseline blood cell counts and indices from medical records. We calculated in-hospital mortality and short-term prognosis, followed by analysis to identify predictors of mortality using hematological parameters. Results: One-third of TB patients were critically ill (35.32%) and required intensive care unit (ICU) admission, while 14.5% had DR-TB, more common in females and smokers. Critically ill patients were older and tended to be non-smokers. DR-TB patients exhibited elevated lymphocyte and monocyte counts but lower neutrophil count and blood indices. Critically ill DS-TB patients had lower hemoglobin (Hb) and platelet (PLT) but higher total leucocytes count (TLC) and mean platelet volume (MPV). In-hospital mortality rate was 29.37%, significantly higher in critically ill DS-TB patients (74.74%). In-hospital mortality was 14-fold higher in critically ill DS-TB patients, 11-fold higher in stable DR-TB patients, and 6-fold higher in patients with comorbidities. Decreased Hb, monocyte level, and neutrophil to lymphocyte ratio (NLR) were significantly associated with in-hospital mortality. Predictors of short-term mortality included critical illness and comorbidities. However, the effect of DR-TB on short-term mortality disappeared. Decreasing Hb and TLC, especially neutrophils were significantly linked to short-term mortality. The utility of Hb in discriminating in-hospital and short-term mortality was very good, with AUC values of 78% and 79%, respectively. Cutoff values of less than 10 mg/dL and 9.75 mg/dL showed sensitivity ranging from 71 to 80% and specificity ranging from 75 to 80%, respectively. Conclusion: This study provides valuable insights into patients with DR-TB and DS-TB with critically illness. We observed elevated lymphocyte and monocyte counts in DR-TB patients, as well as significant alterations in blood indices in critically ill patients. Importantly, the in-hospital mortality was notably higher in critically ill DS-TB patients, highlighting the importance of early recognition and aggressive management in this subgroup. Specifically, certain blood parameters such as hemoglobin, monocytes, neutrophils, and the NLR were associated with an increased risk of both in-hospital and short-term mortality. Furthermore, our findings underscore the prognostic significance of hematological parameters, particularly in resource-limited settings.
- 13 June 2024
- Published by Springer Nature in The Egyptian Journal of Bronchology
- Vol. 18 (1) , 1-13
Open AccessHematological profiles and mortality risk in critically ill and drug-resistant tuberculosis patients: insights from a longitudinal study
Background: While tuberculosis (TB) remains a significant global health threat, data on mortality in critically ill TB patients and those with drug-resistant TB (DR-TB) is limited. This study explores hematological profiles of critically ill TB patients and those with DR-TB, investigating associations with in-hospital and short-term mortality. Methods: A longitudinal study of 269 patients with confirmed TB evaluated baseline blood cell counts and indices from medical records. We calculated in-hospital mortality and short-term prognosis, followed by analysis to identify predictors of mortality using hematological parameters. Results: One-third of TB patients were critically ill (35.32%) and required intensive care unit (ICU) admission, while 14.5% had DR-TB, more common in females and smokers. Critically ill patients were older and tended to be non-smokers. DR-TB patients exhibited elevated lymphocyte and monocyte counts but lower neutrophil count and blood indices. Critically ill DS-TB patients had lower hemoglobin (Hb) and platelet (PLT) but higher total leucocytes count (TLC) and mean platelet volume (MPV). In-hospital mortality rate was 29.37%, significantly higher in critically ill DS-TB patients (74.74%). In-hospital mortality was 14-fold higher in critically ill DS-TB patients, 11-fold higher in stable DR-TB patients, and 6-fold higher in patients with comorbidities. Decreased Hb, monocyte level, and neutrophil to lymphocyte ratio (NLR) were significantly associated with in-hospital mortality. Predictors of short-term mortality included critical illness and comorbidities. However, the effect of DR-TB on short-term mortality disappeared. Decreasing Hb and TLC, especially neutrophils were significantly linked to short-term mortality. The utility of Hb in discriminating in-hospital and short-term mortality was very good, with AUC values of 78% and 79%, respectively. Cutoff values of less than 10 mg/dL and 9.75 mg/dL showed sensitivity ranging from 71 to 80% and specificity ranging from 75 to 80%, respectively. Conclusion: This study provides valuable insights into patients with DR-TB and DS-TB with critically illness. We observed elevated lymphocyte and monocyte counts in DR-TB patients, as well as significant alterations in blood indices in critically ill patients. Importantly, the in-hospital mortality was notably higher in critically ill DS-TB patients, highlighting the importance of early recognition and aggressive management in this subgroup. Specifically, certain blood parameters such as hemoglobin, monocytes, neutrophils, and the NLR were associated with an increased risk of both in-hospital and short-term mortality. Furthermore, our findings underscore the prognostic significance of hematological parameters, particularly in resource-limited settings.
- Open Access
Sinopharm’s BBIBP-CorV Vaccine and ChAdOx1 nCoV-19 Vaccine Are Associated with a Comparable Immune Response against SARS-CoV-2
Coronavirus disease 2019 (COVID-19) has affected millions of people worldwide. During the early stages of vaccination in Egypt, the ChAdOx1 nCoV-19 and BBIBP-CorV vaccines were the most distributed. The aim of this study was to compare the immune responses and short-term efficacies of these two vaccines. We recruited adults who received two doses of either vaccine. Samples were collected after the first dose of ChAdOx1 nCoV-1 and after the second dose of both vaccines. Antibodies against SARS-CoV-2 antigens were measured using LABScreen™ COVID Plus kits, and cell-mediated immune responses were assessed using flow cytometry. Of the 109 recruited subjects, 60 (55%) received the ChAdOx1 nCoV-19 vaccine, and the remainder received the BBIBP-CorV vaccine. The total antibody level did not significantly differ between the two groups. The level of the anti-spike subunit 2 (S2) antibody was significantly higher in the ChAdOx1 nCoV-19 group. The percentages of both total T cells and B cells were unaffected by the type of vaccination. However, the ChAdOx1 nCoV-1 vaccine was significantly associated with a higher percentage of CD8+ cells. The vaccines did not significantly differ in the number or severity of infections postvaccination. None of the participants were admitted to the hospital or died of COVID-19 infection. In conclusion, the BBIBP-CorV vaccine is associated with an immune response and protection against infection that is comparable to that of the ChAdOx1 nCoV-1 vaccine. Follow-up is needed to study the long-term protective effects of both vaccines. Inactivated vaccines are easier to manufacture in developing countries and their limited side effects may lead to better economic benefits by limiting the number of absences from work.
Open AccessSinopharm’s BBIBP-CorV Vaccine and ChAdOx1 nCoV-19 Vaccine Are Associated with a Comparable Immune Response against SARS-CoV-2
Coronavirus disease 2019 (COVID-19) has affected millions of people worldwide. During the early stages of vaccination in Egypt, the ChAdOx1 nCoV-19 and BBIBP-CorV vaccines were the most distributed. The aim of this study was to compare the immune responses and short-term efficacies of these two vaccines. We recruited adults who received two doses of either vaccine. Samples were collected after the first dose of ChAdOx1 nCoV-1 and after the second dose of both vaccines. Antibodies against SARS-CoV-2 antigens were measured using LABScreen™ COVID Plus kits, and cell-mediated immune responses were assessed using flow cytometry. Of the 109 recruited subjects, 60 (55%) received the ChAdOx1 nCoV-19 vaccine, and the remainder received the BBIBP-CorV vaccine. The total antibody level did not significantly differ between the two groups. The level of the anti-spike subunit 2 (S2) antibody was significantly higher in the ChAdOx1 nCoV-19 group. The percentages of both total T cells and B cells were unaffected by the type of vaccination. However, the ChAdOx1 nCoV-1 vaccine was significantly associated with a higher percentage of CD8+ cells. The vaccines did not significantly differ in the number or severity of infections postvaccination. None of the participants were admitted to the hospital or died of COVID-19 infection. In conclusion, the BBIBP-CorV vaccine is associated with an immune response and protection against infection that is comparable to that of the ChAdOx1 nCoV-1 vaccine. Follow-up is needed to study the long-term protective effects of both vaccines. Inactivated vaccines are easier to manufacture in developing countries and their limited side effects may lead to better economic benefits by limiting the number of absences from work.